Genomic Testing Gaps, Chemotherapy Decisions in Young Women With HR+ Breast Cancer: Mitali Shah, MD

Why It Matters

The findings reveal that under‑tested young patients may be over‑treated, inflating costs and exposing them to avoidable toxicity, while also exposing equity gaps that threaten outcomes.

Key Takeaways

• Young women <50 receive chemo despite low Oncotype DX scores
• Testing rates lower in uninsured, Medicaid, and low‑income patients
• Academic centers perform more genomic testing than rural or safety‑net hospitals
• Standardizing reflex Oncotype DX could reduce unnecessary chemotherapy

Pulse Analysis

Hormone‑receptor‑positive breast cancer in premenopausal women has historically been guided by data derived from older, postmenopausal cohorts. The 21‑gene Oncotype DX assay, validated for predicting recurrence and chemotherapy benefit, performs well in older patients but its predictive power is less certain for women under 50. Recent evidence shows that even with low recurrence scores, younger patients often receive adjuvant chemotherapy when tumor stage, grade, or nodal involvement are unfavorable, suggesting clinicians weigh age‑related risk factors alongside genomic results.

Beyond clinical nuance, the analysis spotlights systemic inequities in genomic testing. Studies consistently report lower Oncotype DX utilization among uninsured individuals, Medicaid beneficiaries, and those living in high‑deprivation zip codes. Geographic disparities also emerge: large academic and NCI‑designated centers routinely order the test, whereas rural hospitals, safety‑net facilities, and smaller community practices lag behind. These gaps translate into divergent treatment pathways, potentially compromising survival for underserved populations while inflating costs for those over‑treated.

For payers and health‑system executives, the path forward lies in embedding reflex testing protocols into breast‑cancer pathways. By automatically triggering Oncotype DX for eligible patients, organizations can align therapeutic choices with evidence‑based risk, curtail unnecessary chemotherapy, and reduce variation across sites. Such standardization promises not only better patient outcomes but also measurable savings in drug expenditures and toxicity management, reinforcing the business case for equitable, data‑driven oncology care.